<DOC>
	<DOCNO>NCT01406938</DOCNO>
	<brief_summary>This study ass safety efficacy two different dos two different dose regimen subcutaneous secukinumab patient moderate severe , chronic , plaque-type psoriasis .</brief_summary>
	<brief_title>Efficacy Safety Subcutaneous Secukinumab ( AIN457 ) Moderate Severe Chronic Plaque-type Psoriasis Assessing Different Doses Dose Regimens</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion criterion : Moderate severe plaquetype psoriasis diagnose least 6 month . Severity disease meeting follow three criterion : PASI score 12 great , Investigator 's Global Assessment ( IGA ) score 3 great Total body surface area ( BSA ) affect 10 % great . Inadequate control prior use topical treatment , phototherapy and/or systemic therapy . Exclusion criterion : Current form psoriasis chronic plaquetype psoriasis ( example , pustular , erythrodermic , guttate ) . Current druginduced psoriasis . Previous use secukinumab drug target IL17 IL17 receptor . Significant medical problem uncontrolled hypertension , congestive heart failure condition significantly immunocompromises subject . Hematological abnormality . History ongoing , chronic recurrent infectious disease , evidence untreated tuberculosis . History lymphoproliferative disease history malignancy organ system within past 5 year . Pregnant nursing ( lactate ) woman . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>plaque</keyword>
	<keyword>inflammatory skin disease</keyword>
	<keyword>scaly patch</keyword>
	<keyword>AIN457</keyword>
	<keyword>secukinumab</keyword>
	<keyword>Moderate Severe Plaque-type Psoriasis</keyword>
</DOC>